Literature DB >> 17224331

Long-term oral lysine supplementation in lysinuric protein intolerance.

Laura M Tanner1, Kirsti Näntö-Salonen, Harri Niinikoski, Kirsi Huoponen, Olli Simell.   

Abstract

In lysinuric protein intolerance (LPI), defective transport of cationic amino acids at the basolateral membrane of the polar epithelial cells in the intestine and renal tubules leads to decreased intestinal absorption and excessive renal loss of lysine, arginine, and ornithine. Citrulline supplementation partially restores the function of the urea cycle that is impaired by deficiency of arginine and ornithine, but does not correct the chronic lysine deficiency. Previous attempts to supplement lysine orally have been hindered by profuse diarrhea, probably caused by excess lysine remaining unabsorbed in the gut. However, individually adjusted minute doses of L-lysine hydrochloride at mealtimes are tolerated well, but the long-term benefits of this therapy remain unknown. The aim of the study was to investigate the long-term benefits and possible adverse effects of oral lysine supplementation in patients with LPI. Supplementation of meals with low doses of oral lysine improved fasting plasma lysine concentrations in 27 Finnish patients with LPI without causing hyperammonemia or other recognizable side effects during 12 months of follow-up. In conclusion, low-dose oral lysine supplementation is potentially beneficial to patients with LPI and can be started safely at an early age.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17224331     DOI: 10.1016/j.metabol.2006.09.011

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  9 in total

1.  Growth hormone therapy is safe and effective in patients with lysinuric protein intolerance.

Authors:  Harri Niinikoski; Risto Lapatto; Matti Nuutinen; Laura Tanner; Olli Simell; Kirsti Näntö-Salonen
Journal:  JIMD Rep       Date:  2011-06-22

2.  A global Slc7a7 knockout mouse model demonstrates characteristic phenotypes of human lysinuric protein intolerance.

Authors:  Bridget M Stroup; Ronit Marom; Xiaohui Li; Chih-Wei Hsu; Cheng-Yen Chang; Luan D Truong; Brian Dawson; Ingo Grafe; Yuqing Chen; Ming-Ming Jiang; Denise Lanza; Jennie Rose Green; Qin Sun; J P Barrish; Safa Ani; Audrey E Christiansen; John R Seavitt; Mary E Dickinson; Farrah Kheradmand; Jason D Heaney; Brendan Lee; Lindsay C Burrage
Journal:  Hum Mol Genet       Date:  2020-08-03       Impact factor: 6.150

Review 3.  Overview of symptoms and treatment for lysinuric protein intolerance.

Authors:  Atsuko Noguchi; Tsutomu Takahashi
Journal:  J Hum Genet       Date:  2019-06-18       Impact factor: 3.172

4.  First reported case of lysinuric protein intolerance (LPI) in Lithuania, confirmed biochemically and by DNA analysis.

Authors:  Loreta Cimbalistiene; Willy Lehnert; Kirsi Huoponen; Vaidutis Kucinskas
Journal:  J Appl Genet       Date:  2007       Impact factor: 3.240

5.  Novel SLC7A7 large rearrangements in lysinuric protein intolerance patients involving the same AluY repeat.

Authors:  Mariona Font-Llitjós; Benjamín Rodríguez-Santiago; Meritxell Espino; Ruth Sillué; Sandra Mañas; Laia Gómez; Luis A Pérez-Jurado; Manuel Palacín; Virginia Nunes
Journal:  Eur J Hum Genet       Date:  2008-08-20       Impact factor: 4.246

6.  Lysinuric Protein Intolerance Presenting with Multiple Fractures.

Authors:  Jennifer E Posey; Lindsay C Burrage; Marcus J Miller; Pengfei Liu; Matthew T Hardison; Sarah H Elsea; Qin Sun; Yaping Yang; Alecia S Willis; Alan E Schlesinger; Carlos A Bacino; Brendan H Lee
Journal:  Mol Genet Metab Rep       Date:  2014

7.  Lysinuric protein intolerance in a family of Mexican ancestry with a novel SLC7A7 gene deletion. Case report and review of the literature.

Authors:  David Carpentieri; Margaret F Barnhart; Kyrieckos Aleck; Tamir Miloh; Daphne deMello
Journal:  Mol Genet Metab Rep       Date:  2015-01-10

8.  Immune Dysregulation Mimicking Systemic Lupus Erythematosus in a Patient With Lysinuric Protein Intolerance: Case Report and Review of the Literature.

Authors:  Josefina Longeri Contreras; Mabel A Ladino; Katherine Aránguiz; Gonzalo P Mendez; Zeynep Coban-Akdemir; Bo Yuan; Richard A Gibbs; Lindsay C Burrage; James R Lupski; Ivan K Chinn; Tiphanie P Vogel; Jordan S Orange; M Cecilia Poli
Journal:  Front Pediatr       Date:  2021-05-20       Impact factor: 3.418

Review 9.  Single amino acid supplementation in aminoacidopathies: a systematic review.

Authors:  Danique van Vliet; Terry G J Derks; Margreet van Rijn; Martijn J de Groot; Anita MacDonald; M Rebecca Heiner-Fokkema; Francjan J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2014-01-13       Impact factor: 4.123

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.